Evidence map›Paper›PMID 40698812›Full record

Observational studyAntimicrobial agents and chemotherapy2025

Personalized tobramycin dosing in children with cystic fibrosis: an AUC

Kiera H Harwood, Stephen Duffull, Shivanthan Shanthikumar, Alice Lei, Sarath Ranganathan, Phil Robinson, Indy Sandaradura, Tony Lai, Amanda Gwee

Abstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kiera H HarwoodDepartment of Paediatrics, The University of Melbourne, , Parkville, Victoria, Australia.ORCID 0009-0006-9507-2497
Stephen DuffullCertara, Princeton, New Jersey, USA.
Shivanthan ShanthikumarDepartment of Paediatrics, The University of Melbourne, , Parkville, Victoria, Australia.
Alice LeiAntimicrobials Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
Sarath RanganathanDepartment of Paediatrics, The University of Melbourne, , Parkville, Victoria, Australia.
Phil RobinsonDepartment of Paediatrics, The University of Melbourne, , Parkville, Victoria, Australia.
Indy SandaraduraThe Children's Hospital at Westmead, Sydney, New South Wales, Australia.ORCID 0000-0002-9457-8262
Tony LaiThe Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Amanda GweeDepartment of Paediatrics, The University of Melbourne, , Parkville, Victoria, Australia.ORCID 0000-0003-4016-8986

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tobramycin is commonly used for the treatment of pulmonary exacerbations in children with cystic fibrosis (CF). Currently, a standard dose of 10 mg/kg daily is used in all children. We aim to develop a population pharmacokinetic (popPK) model of tobramycin in children with CF and determine the: (i) effect of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on tobramycin pharmacokinetics (PK); (ii) attainment of the commonly used serum steady state area under the concentration-time curve target (AUC

Indexed as

Anti-Bacterial AgentsCystic FibrosisTobramycinAdolescentAminophenolsArea Under CurveChildChild, PreschoolCystic Fibrosis Transmembrane Conductance RegulatorFemaleHumansInfantInfant, NewbornMalePrecision MedicineProspective StudiesAminophenolsAnti-Bacterial AgentsCystic Fibrosis Transmembrane Conductance RegulatorivacaftorQuinolonesTobramycinaminoglycosidescystic fibrosispopulation pharmacokinetics

Identifiers

PMID40698812
PMCPMC12406653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.